A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency (foresiGHt)

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

A 38-week dosing trial of lonapegsomatropin, a long-acting growth hormone product, administered once-a-week versus placebo-control. A daily somatropin product arm is also included to assist clinical judgement on the trial results. A total of 264 adults (males and females) with growth hormone deficiency were included. Randomization occurred in a 1:1:1 ratio (lonapegsomatropin: placebo: daily somatropin product). This is a global trial conducted in, but not limited to, the United States, Europe, and Asia.

Study Overview

• Status: Completed
• Conditions: Endocrine System Diseases; Growth Hormone Deficiency; Hormone Deficiency
• Intervention / Treatment: Drug: Lonapegsomatropin; Other: Placebo; Drug: Somatropin

• Study Type: Interventional
• Enrollment (Actual): 264
• Phase: Phase 3

Contacts and Locations

Study Locations

• Armenia
  • Yerevan, Armenia, 0075
    • Ascendis Pharma Investigational Site
• Australia
  • New South Wales
    • Saint Leonards, New South Wales, Australia, 2065
      • Ascendis Pharma Investigational Site
    • Sydney, New South Wales, Australia, 2109
      • Ascendis Pharma Investigational Site
  • Victoria
    • Box Hill, Victoria, Australia, 3128
      • Ascendis Pharma Investigational Site
    • Fitzroy, Victoria, Australia, 3065
      • Ascendis Pharma Investigational Site
    • Parkville, Victoria, Australia, 3050
      • Ascendis Pharma Investigational Site
  • Western Australia
    • Perth, Western Australia, Australia, 6009
      • Ascendis Pharma Investigational Site
• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V6Z 1Y6
      • Ascendis Pharma Investigational Site
  • Nova Scotia
    • Halifax, Nova Scotia, Canada, B3H 1V7
      • Ascendis Pharma Investigational Site
• Denmark
  • København, Denmark, 2100
    • Ascendis Pharma Investigational Site
• France
  • Lyon, France, 69677
    • Ascendis Pharma Investigational Site
  • Marseille, France, 13385
    • Ascendis Pharma Investigational Site
  • Nantes, France, 44093
    • Ascendis Pharma Investigational Site
  • Paris, France, 75013
    • Ascendis Pharma Investigational Site
• Georgia
  • Tbilisi, Georgia, 0144
    • Ascendis Pharma Investigational Site
  • Tbilisi, Georgia, 0159
    • Ascendis Pharma Investigational Site
• Germany
  • Bayern
    • München, Bayern, Germany, 80336
      • Ascendis Pharma Investigational Site
• Greece
  • Thessaloníki, Greece, 546 42
    • Ascendis Pharma Investigational Site
  • Attica
    • Athens, Attica, Greece, 10676
      • Ascendis Pharma Investigational Site
    • Athens, Attica, Greece, 11527
      • Ascendis Pharma Investigational Site
  • Central Macedonia
    • Thessaloníki, Central Macedonia, Greece, 54636
      • Ascendis Pharma Investigational Site
• Israel
  • Beer Sheva, Israel, 8410100
    • Ascendis Pharma Investigational Site
  • Haifa, Israel, 31048
    • Ascendis Pharma Investigational Site
  • Petah Tikva, Israel, 4941480
    • Ascendis Pharma Investigational Site
  • Tel Aviv, Israel, 6423906
    • Ascendis Pharma Investigational Site
• Italy
  • Genova, Italy, 16132
    • Ascendis Pharma Investigational Site
  • Rome, Italy, 00161
    • Ascendis Pharma Investigational Site
  • Rome, Italy, 00168
    • Ascendis Pharma Investigational Site
  • Rozzano, Italy, 20089
    • Ascendis Pharma Investigational Site
• Japan
  • Chiba, Japan, 260-8677
    • Ascendis Pharma Investigational Site
  • Fukuoka, Japan, 812-8582
    • Ascendis Pharma Investigational Site
  • Kagoshima, Japan, 890-8520
    • Ascendis Pharma Investigational Site
  • Kawasaki, Japan, 216-8511
    • Ascendis Pharma Investigational Site
  • Nagakute, Japan, 480-1195
    • Ascendis Pharma Investigational Site
  • Okayama, Japan, 700-8558
    • Ascendis Pharma Investigational Site
  • Osaka, Japan, 550-0006
    • Ascendis Pharma Investigational Site
  • Tokyo, Japan, 108-8329
    • Ascendis Pharma Investigational Site
  • Yamagata, Japan, 990-9585
    • Ascendis Pharma Investigational Site
  • Hyogo
    • Kobe, Hyogo, Japan, 650-0047
      • Ascendis Pharma Investigational Site
  • Kanagawa
    • Kawasaki, Kanagawa, Japan, 211-8533
      • Ascendis Pharma Investigational Site
    • Yokohama, Kanagawa, Japan, 222-0036
      • Ascendis Pharma Investigational Site
    • Yokohama, Kanagawa, Japan, 236-004
      • Ascendis Pharma Investigational Site
  • Nagano
    • Matsumoto, Nagano, Japan, Japan
      • Ascendis Pharma Investigational Site
  • Nara
    • Kashihara, Nara, Japan, 634-8522
      • Ascendis Pharma Investigational Site
  • Okinawa
    • Ishikawa, Okinawa, Japan, 920-0293
      • Ascendis Pharma Investigational Site
  • Osaka
    • Suita, Osaka, Japan, 565-0871
      • Ascendis Pharma Investigational Site
• Korea, Republic of
  • Seoul, Korea, Republic of, 03722
    • Ascendis Pharma Investigational Site
  • Seoul, Korea, Republic of, 05278
    • Ascendis Pharma Investigational Site
  • Seoul, Korea, Republic of, 06591
    • Ascendis Pharma Investigational Site
  • Suwon, Korea, Republic of, 443-721
    • Ascendis Pharma Investigational Site
• Malaysia
  • George Town, Malaysia, 10450
    • Ascendis Pharma Investigational Site
  • Kota Bharu, Malaysia, 16150
    • Ascendis Pharma Investigational Site
  • Melaka, Malaysia, 75400
    • Ascendis Pharma Investigational Site
  • Putrajaya, Malaysia, 62250
    • Ascendis Pharma Investigational Site
• Netherlands
  • Leiden, Netherlands, 2300
    • Ascendis Pharma Investigational Site
• New Zealand
  • Wellington, New Zealand, 6021
    • Ascendis Pharma Investigational Site
  • Manawatu-Wanganui
    • Palmerston North, Manawatu-Wanganui, New Zealand, 4440
      • Ascendis Pharma Investigational Site
• Poland
  • Kraków, Poland, 31-501
    • Ascendis Pharma Investigational Site
  • Poznań, Poland, 60-355
    • Ascendis Pharma Investigational Site
  • Warsaw, Poland, 03-242
    • Ascendis Pharma Investigational Site
  • Wrocław, Poland, 50-367
    • Ascendis Pharma Investigational Site
  • Łódź, Poland, 93-338
    • Ascendis Pharma Investigational Site
• Romania
  • Bucharest, Romania, 11868
    • Ascendis Pharma Investigational Site
  • Iaşi, Romania, 700106
    • Ascendis Pharma Investigational Site
  • Timişoara, Romania, 300723
    • Ascendis Pharma Investigational Site
• Serbia
  • Belgrade, Serbia, 11000
    • Ascendis Pharma Investigational Site
  • Kragujevac, Serbia, 34000
    • Ascendis Pharma Investigational Site
• Slovakia
  • Bratislava, Slovakia, 82606
    • Ascendis Pharma Investigational Site
  • Lubochna, Slovakia, 3491
    • Ascendis Pharma Investigational Site
• Spain
  • Alicante, Spain, 3010
    • Ascendis Pharma Investigational Site
  • Barcelona, Spain, 8035
    • Ascendis Pharma Investigational Site
  • Barcelona, Spain, 8041
    • Ascendis Pharma Investigational Site
  • Madrid, Spain, 28006
    • Ascendis Pharma Investigational Site
  • Santiago De Compostela, Spain, 15706
    • Ascendis Pharma Investigational Site
  • Sevilla, Spain, 41013
    • Ascendis Pharma Investigational Site
• Turkey
  • Ankara, Turkey, 06560
    • Ascendis Pharma Investigational Site
  • Antalya, Turkey, 07070
    • Ascendis Pharma Investigational Site
  • Aydın, Turkey, 09010
    • Ascendis Pharma Investigational Site
  • Kayseri, Turkey, 38039
    • Ascendis Pharma Investigational Site
  • İzmir, Turkey, 35100
    • Ascendis Pharma Investigational Site
  • İzmit, Turkey, 41001
    • Ascendis Pharma Investigational Site
• Ukraine
  • Ivano-Frankivs'k, Ukraine, 76008
    • Ascendis Pharma Investigational Site
  • Kharkiv, Ukraine, 61103
    • Ascendis Pharma Investigational Site
  • Kyiv, Ukraine, 04114
    • Ascendis Pharma Investigational Site
  • Kyiv, Ukraine, 03115
    • Ascendis Pharma Investigational Site
  • Kyiv, Ukraine, 04001
    • Ascendis Pharma Investigational Site
  • Vinnytsya, Ukraine, 21010
    • Ascendis Pharma Investigational Site
• United Kingdom
  • Cardiff, United Kingdom, CF14 4XW
    • Ascendis Pharma Investigational Site
  • Coventry, United Kingdom, CV2 2DX
    • Ascendis Pharma Investigational Site
  • Leeds, United Kingdom, LS9 7TF
    • Ascendis Pharma Investigational Site
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35205
      • Ascendis Pharma Investigational Site
  • Arizona
    • Phoenix, Arizona, United States, 85048
      • Ascendis Pharma Investigational Site
  • California
    • Fresno, California, United States, 93720
      • Ascendis Pharma Investigational Site
    • Los Angeles, California, United States, 90048
      • Ascendis Pharma Investigational Site
    • Los Angeles, California, United States, 90095
      • Ascendis Pharma Investigational Site
    • Palo Alto, California, United States, 94304
      • Ascendis Pharma Investigational Site
    • Torrance, California, United States, 90509
      • Ascendis Pharma Investigational Site
  • Illinois
    • Chicago, Illinois, United States, 60611
      • Ascendis Pharma Investigational Site
  • Indiana
    • Indianapolis, Indiana, United States, 46202
      • Ascendis Pharma Investigational Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Ascendis Pharma Investigational Site
  • Michigan
    • Dearborn, Michigan, United States, 48126
      • Ascendis Pharma Investigational Site
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Ascendis Pharma Investigational Site
  • Missouri
    • Saint Louis, Missouri, United States, 63110
      • Ascendis Pharma Investigational Site
  • Nevada
    • Las Vegas, Nevada, United States, 89148
      • Ascendis Pharma Investigational Site
    • Reno, Nevada, United States, 89511
      • Ascendis Pharma Investigational Site
  • New York
    • New York, New York, United States, 10017
      • Ascendis Pharma Investigational Site
    • New York, New York, United States, 10021
      • Ascendis Pharma Investigational Site
  • North Carolina
    • Morehead City, North Carolina, United States, 28557
      • Ascendis Pharma Investigational Site
  • Oregon
    • Portland, Oregon, United States, 97239
      • Ascendis Pharma Investigational Site
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15212
      • Ascendis Pharma Investigational Site
  • Texas
    • Dallas, Texas, United States, 75390
      • Ascendis Pharma Investigational Site
    • San Antonio, Texas, United States, 78232
      • Ascendis Pharma Investigational Site
  • Washington
    • Seattle, Washington, United States, 98108
      • Ascendis Pharma Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 23 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

1. Age between 23 and 80 years, inclusive, at screening.

2. Adult Growth Hormone Deficiency (AGHD) Diagnosis Criteria

   • For adult-onset AGHD: documented history of structural hypothalamic-pituitary disease, hypothalamic-pituitary surgery, cranial irradiation, 1-4 non-GH pituitary hormone deficiencies, a proven genetic cause of GHD, or traumatic brain injury (TBI).
   • Participants with childhood-onset GHD must have had GH axis re-assessed at final height.
   • In participants with TBI as a cause of GHD, GHD must be confirmed by GH -stimulation testing performed at least 12 months after the injury.

   A. For all countries except Japan: participants must have satisfied at least one of the following criteria:

   1. Insulin tolerance test: peak growth hormone (GH) <=5 ng/mL

   2. Glucagon stimulation test according to body mass index (BMI)

      • i. BMI <=30 kg/m^2: peak GH <=3 ng/mL
      • ii. BMI >30 kg/m^2: peak GH <=1 ng/mL
   3. Three or four pituitary axis deficiencies (i.e., adrenal, thyroid, gonadal, and/or vasopressin; not including GH) with insulin-like growth factor-1 standard deviation score (IGF-1 SDS) <= -2.0 at screening
   4. Macimorelin test: peak GH <=2.8 ng/mL

   5. Growth hormone releasing hormone (GHRH) + arginine test according to BMI:

      • i. BMI <25 kg/m^2, peak GH <11 ng/mL
      • ii. BMI >=25-<=30 kg/m^2, peak GH <8 ng/mL
      • iii. BMI >30 kg/m^2, peak GH <4 ng/mL

   B. For Japan only: Participants with AGHD and deficiency of at least one non-GH pituitary hormones need to satisfy one of the following GH stimulation tests. Participants with GHD without additional non-GH pituitary hormone deficiencies with or without and evidence of intracranial structure disorder need to satisfy at least 2 of the following stimulation tests:

   1. Insulin tolerance test: peak GH <=1.8 ng/mL
   2. Glucagon test: peak GH <=1.8 ng/mL
   3. Growth Hormone Releasing Peptide-2 (GHRP-2) tolerance test: peak GH <=9 ng/mL
3. IGF-1 SDS <= -1.0 at screening as measured by central laboratory.
4. hGH treatment naïve or no exposure to hGH therapy or GH secretagogue for at least 12 months prior to screening.
5. For participants on hormone replacement therapies for any hormone deficiencies other than GH (e.g., adrenal, thyroid, estrogen, testosterone) must be on adequate and stable doses for >=6 weeks prior to and throughout screening.
6. For participants not on glucocorticoid replacement therapy, documentation of adequate adrenal function at screening defined as: morning (6:00-10:00 AM) serum cortisol >15.0 mcg/dL (measured at central laboratory) and/or adrenocorticotropic hormone (ACTH) stimulation test or insulin tolerance test with serum cortisol >18.0 mcg/dL at or within 90 days prior to screening.
7. For males not on testosterone replacement therapy: morning (6:00 - 10:00AM) total testosterone within normal limits for age.
8. On a stable diet and exercise regime at screening with no intention to modify diet or exercise pattern during the trial, i.e., no weight reduction program intended during the trial or within the last 90 days prior to or through screening.
9. No plans to undergo bariatric surgery during the trial.
10. Fundoscopy at screening without signs/symptoms of intracranial hypertension or diabetic retinopathy above stage 2 / moderate or above or any other retinal disease contraindicated to growth hormone therapy. For participants with a diagnosis of diabetes mellitus at screening, this must be documented with a fundus photograph.
11. Able and willing to provide a written informed consent and authorization for protected health information (PHI) disclosure in accordance with Good Clinical Practice (GCP).
12. Serum free thyroxine (fT4) in the normal range at screening as measured by central laboratory.

Exclusion Criteria

1. Known Prader-Willi Syndrome and/or other genetic diseases that may have an impact on an endpoint.

2. Diabetes mellitus at screening if any of the following criteria are met:

   1. Poorly controlled diabetes, defined as HbA1c >7.5% at screening.
   2. Diabetes mellitus (defined as HbA1c >=6.5% and/or fasting plasma glucose >=126 mg/dL and/or plasma glucose >=200 mg/dL two hours after oral glucose tolerance test) diagnosed <26 weeks prior to screening
   3. Change in diabetes regimen (includes dose adjustment) within <90 days prior and throughout screening
   4. Use of any diabetes drugs other than metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors for a cumulative duration of greater than 4 weeks within 12 months prior to screening
   5. Diabetes-related complications at screening (i.e., nephropathy as judged by the investigator, neuropathy requiring pharmacological treatment, retinopathy stage 2/moderate and above within 90 days prior to screening or during screening)

3. Active malignant disease or history of malignancy. Exceptions to this exclusion criterion:

   1. Resection of in situ carcinoma of the cervix uteri
   2. Complete eradication of squamous cell or basal cell carcinoma of the skin
   3. Participants with GHD attributed to treatment of intracranial malignant tumors or leukemia, provided that a recurrence-free survival period of at least 5 years prior to screening is documented in the participant's file (based on a Magnetic Resonance Imaging (MRI) result for intracranial malignant tumors)
4. Evidence of growth of pituitary adenoma or other benign intracranial tumor within the last 12 months before screening.
5. Participants with acromegaly without remission / with documented remission less than 24 months prior to screening.
6. Participants with Cushing's disease without remission / with documented remission less than 24 months prior to screening.
7. Participants with prior cranial irradiation or hypothalamic-pituitary surgery: the procedure was to take place less than 12 months prior to screening.
8. Estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m^2 determined based on Modification of Diet in Renal Disease (MDRD) equation.
9. Hepatic transaminases (i.e., aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) >3 times the upper limit of normal.
10. Heart failure New York Heart Association (NYHA) class 3 or greater (NYHA 1994).
11. Q-T interval, corrected by Fridericia's method (QTcF) >= 451 milliseconds on 12-lead electrocardiogram (ECG) at screening.
12. Poorly controlled hypertension, defined as supine systolic blood pressure >159 mmHg and/or supine diastolic blood pressure >95 mmHg at screening.
13. Cerebrovascular accident within 5 years prior to screening.
14. Anabolic steroids (other than gonadal steroid replacement therapy) or oral/intravenous/intramuscular corticosteroids within 90 days prior to or throughout screening.
15. Currently using or have used within 26 weeks prior to screening any weight-loss or appetite-suppressive medications including orlistat, zonisamide, lorcaserin, bupropion, topiramate, sibutramine, stimulants, glucagon-like peptide 1 (GLP-1) receptor agonists, sodium-dependent glucose cotransporters (SGLT-2) inhibitors or medications that affects IGF-1 or GH measurements including cabergoline at doses above 0.5 mg weekly or bromocriptine at doses above 20 mg weekly.
16. Known history of hypersensitivity and/or idiosyncrasy to any of the test compounds (somatropin) or excipients employed in this trial.
17. Known history of neutralizing anti-hGH antibodies.
18. Inability to undergo scanning by dual-energy x-ray absorptiometry (DXA) or a non-interpretable DXA scan at screening.
19. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential (i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile) and not using adequate contraceptive methods.
20. Male participants must use a condom, or his female partner of childbearing potential must use an effective form of contraception as described above, from the beginning of screening to the last trial visit.
21. Known substance abuse or known (or previous) eating disorders, including anorexia nervosa, bulimia and severe gastrointestinal disease affecting normal eating (as judged by the investigator).
22. Any disease or condition that, in the judgement of the investigator, may make the subject unlikely to comply with the requirements of the trial or any condition that presents undue risk from the investigational product or procedures.
23. Participation in another interventional clinical trial involving an investigational compound within 26 weeks prior to screening or in parallel to this trial.
24. Currently using or have used within the last 3 days prior to screening: biotin >0.03 mg/day from supplements
25. Known history of positive results of tests for human immunodeficiency virus (HIV) antibodies or hepatitis B and/or C (exceptions if vaccinated towards Hepatitis B virus and Hepatitis C virus).
26. Any of the following: acute critical illness, and complications following open heart surgery, abdominal surgery, multiple accidental traumas, acute respiratory failure, or similar conditions within 180 days prior to screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lonapegsomatropin; Lonapegsomatropin administered once-weekly by subcutaneous injection.	Drug: Lonapegsomatropin; Due to the different human growth hormone (hGH) dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.
Placebo Comparator: Placebo; Placebo for Lonapegsomatropin administered once-weekly by subcutaneous injection.	Other: Placebo; The placebo for lonapegsomatropin drug product contained the same excipients as lonapegsomatropin drug product but does not contain lonapegsomatropin itself. The placebo solution was administered by subcutaneous (SC) injection via syringe and needle. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups and the placebo received the same dose volume as if they were randomized to once-weekly lonapegsomatropin.
Active Comparator: Somatropin; Somatropin administered once-daily by subcutaneous injection.	Drug: Somatropin; Somatropin solution is provided in a pre-filled pen intended for daily subcutaneous injection. Due to the different hGH dose requirements, depending on participant's age and concomitant use of oral estrogen, this trial has 3 dosing groups per arm, followed by gradual increasing dose titration to a target maintenance dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Trunk Percent Fat at Week 38	Trunk percent fat was assessed by dual-energy X-ray absorptiometry.	Baseline, Week 38

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Total Body Lean Mass at Week 38	Total body lean mass was assessed by dual-energy X-ray absorptiometry.	Baseline, Week 38
Change From Baseline in Trunk Fat Mass at Week 38	Trunk fat mass was assessed by dual-energy X-ray absorptiometry.	Baseline, Week 38
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation	An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE was considered a TEAE if it occurred on or after the first dose of investigational product and was not present prior to the first dose, or it was present at the first dose but increased in severity during the trial. A serious AE is any untoward medical occurrence at any dose: resulted in death; was life threatening; required prolong inpatient hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect or was considered a significant medical event by the investigator.	Up to 38 weeks

Collaborators and Investigators

• Sponsor: Ascendis Pharma Endocrinology Division A/S

Study record dates

Study Major Dates

• Study Start (Actual): December 3, 2020
• Primary Completion (Actual): November 2, 2023
• Study Completion (Actual): December 1, 2023

Study Registration Dates

• First Submitted: October 29, 2020
• First Submitted That Met QC Criteria: October 29, 2020
• First Posted (Actual): November 4, 2020

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 20, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Keywords: Growth Hormone Deficiency; Prodrug; Human Growth Hormone; hGH; GHD; Growth Failure; Growth Hormone Replacement Therapy; Sustained Release Growth Hormone; Adult Growth Hormone Deficiency; rhGH; Lonapegsomatropin; TransCon hGH; Long-Acting Growth Hormone
• Additional Relevant MeSH Terms: Bone Diseases; Musculoskeletal Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Hypothalamic Diseases; Pituitary Diseases; Bone Diseases, Endocrine; Bone Diseases, Developmental; Dwarfism; Hypopituitarism; Endocrine System Diseases; Dwarfism, Pituitary
• Other Study ID Numbers: TCH-306; 2020-000929-42 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No